Navigation Links
World's Top 20 Pharmaceutical Companies Deploy Revolutionary H-Cube(R) From ThalesNano Inc.
Date:7/16/2008

BUDAPEST, Hungary and LONDON and PRINCETON, New Jersey, July 16 /PRNewswire/ -- ThalesNano Inc. today announced, that within three years from the original introduction of its H-Cube product, 20 out of the top 20 pharmaceutical companies have introduced and adopted the technology.

The H-Cube(R) Continuous-flow Hydrogenation Reactor is a bench-top standalone hydrogenation reactor, uniquely combining continuous-flow chemistry with endogenous on-demand hydrogen generation and a disposable catalyst cartridge system. It allows safe, fast and cost-efficient hydrogenation with superior yield when compared to conventional methods. The H-Cube and the other novel Cube series flow reactor systems developed by ThalesNano Inc. are showing tremendous benefits in the drug discovery process including shorted development time, increased cost efficiency and reduced environmental impact.

"Having all of the top 20 pharmaceutical companies as H-Cube users is a real testimony that the instrument is changing the process of how drugs are developed and the benefits that can be derived as a result", said Dr. Laszlo Urge, CEO of ThalesNano Inc. "Our early customers are now using our technology at multiple sites on four continents. H-Cube has become their first line of technology for catalytic hydrogenations. After establishing our continuous process technology in the discovery labs of the life sciences industry we are moving into the early scale up and full production with the new versions of the systems."

Dr. Ferenc Darvas, President and chairman of ThalesNano Inc. said. "It is clear that our strategy of providing a disruptive technology to the industry is working. The benefits of these technologies over conventional batch chemistry include the rapid synthesis of organic compounds, in particular under until now unrealizable hazardous reaction conditions. Further benefits include "Green Chemistry" by minimizing waste, energy consumption and raw material use, lab automation, and rapid scale-up from mg to kg quantities, which reduces CAPEX and OPEX while speeding time to market."

For more information please go to: http://www.thalesnano.com

About ThalesNano Inc.:

ThalesNano is a world-leading provider of continuous process chemistry instruments in the rapidly developing market of laboratory and process scale flow reactors. The company has the widest portfolio of bench-top continuous process instruments. Its R&D 100 award winning H-Cube(R) continuous-flow hydrogenation reactor and the pilot plant scale version H-Cube Midi(TM) are used in hundreds of laboratories in four continents and have become the new industry standard for hydrogenation.

Contact: Laszlo Urge, Ph.D., CEO, e-mail: ceodirect@thalesnano.com, Telephone: +36-1-880-8500


'/>"/>
SOURCE ThalesNano Nanotechnology Inc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Maryland Science Center Unveils Anatomical Exhibition, Body Worlds 2, on Saturday, February 2
2. Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Televisions 13th Annual Multi-Platform Stop Breast Cancer For Life Campaign
3. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
4. Amylin Pharmaceuticals to Webcast Second Quarter Results
5. Simcere Pharmaceutical Group to Announce Second Quarter 2008 Earnings on Tuesday, August 5, 2008
6. ViroPharma To Acquire Lev Pharmaceuticals
7. Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
8. Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board
9. WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
10. Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp.
11. Alexion Pharmaceuticals Invites You to Participate in its Second Quarter 2008 Results Conference Call and Web Cast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... Avomeen Analytical Services, an ... its 2017 Science Student Award. The scholarship program is dedicated to helping those ... defray the costs of obtaining their science education. , Avomeen began the annual ...
(Date:9/18/2017)... ... 2017 , ... Transportable biomass conversion facilities and the economics ... the topic of a September 27 webinar hosted by the Waste ... biomass conversion facilities for producing biochar, briquettes, and torrefied wood, biomass supply chains ...
(Date:9/17/2017)... ... 2017 , ... GeneOne Life Science, Inc. announces that it ... (KMFDS) for an Investigational New Drug application for a Phase I/IIa study of ... study in Korea represents the second clinical trial for GLS-5300. , A ...
(Date:9/14/2017)... , ... September 14, 2017 ... ... the launch of its CliniControlâ„¢ (CC) product portfolio, clinically-relevant starting and ancillary ... translation of human Mesenchymal Stem/Stromal Cell (hMSC)-based therapies. The CliniControl product portfolio ...
Breaking Biology Technology:
(Date:4/18/2017)... April 18, 2017  Socionext Inc., a global expert in SoC-based ... edge server, the M820, which features the company,s hybrid codec technology. ... by Tera Probe, Inc., will be showcased during the upcoming Medtec ... show at the Las Vegas Convention Center ... Click here ...
(Date:4/13/2017)... , April 13, 2017 According to a new ... Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, ... IAM Market is expected to grow from USD 14.30 Billion in 2017 ... (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... 2017 No two people are believed ... New York University Tandon School of Engineering and ... that partial similarities between prints are common enough ... phones and other electronic devices can be more ... lies in the fact that fingerprint-based authentication systems ...
Breaking Biology News(10 mins):